Investor Relations | BenevolentAI (2024)

About us
- Our business model
- Our leadership
- Sustainability
  - COVID-19
  - Data Diversity Initiative
  - AI principles
  - ESG
- Publications
Benevolent Platform
- BenAI Engine
- End-to-End Drug Discovery
Pipeline
- BEN-8744 | Ulcerative colitis
- BEN-28010 | Glioblastoma multiforme
- BEN-34712 | ALS
- Parkinson's disease
- Fibrosis
Partnering
Investors
- Announcements
  - Announcement alerts
- Reports and presentations
- General meetings
- Governance
- Share Capital
- Business combination
- Financial calendar
- Investor resources
- Analyst coverage
News and media
- Press releases and in the media
- Blog and videos
- Events
- Newsletter
- Press kit
Careers
- Culture blog
- Join our team

- Our business model
  
  About us
  
  We use AI to empower scientists to uncover new insights from data, helping to accelerate innovation and increase the probability of discovering a successful drug.
  
  About us
- Our leadership
  
  About us
  
  We use AI to empower scientists to uncover new insights from data, helping to accelerate innovation and increase the probability of discovering a successful drug.
  
  About us
- - COVID-19
    
    About us
    
    We use AI to empower scientists to uncover new insights from data, helping to accelerate innovation and increase the probability of discovering a successful drug.
    
    About us
  - Data Diversity Initiative
    
    About us
    
    We use AI to empower scientists to uncover new insights from data, helping to accelerate innovation and increase the probability of discovering a successful drug.
    
    About us
  - AI principles
    
    About us
    
    We use AI to empower scientists to uncover new insights from data, helping to accelerate innovation and increase the probability of discovering a successful drug.
    
    About us
  - ESG
    
    About us
    
    We use AI to empower scientists to uncover new insights from data, helping to accelerate innovation and increase the probability of discovering a successful drug.
    
    About us
  Sustainability
  
  About us
  
  We use AI to empower scientists to uncover new insights from data, helping to accelerate innovation and increase the probability of discovering a successful drug.
  
  About us
- Publications
  
  About us
  
  We use AI to empower scientists to uncover new insights from data, helping to accelerate innovation and increase the probability of discovering a successful drug.
  
  About us
About us

About us

We use AI to empower scientists to uncover new insights from data, helping to accelerate innovation and increase the probability of discovering a successful drug.

About us
- BenAI Engine
  
  Benevolent Platform
  
  A versatile, scalable and robust AI-enabled drug discovery platform built with expert scientists, leveraging multi-modal data foundations.
  
  Benevolent Platform
  See Also
  BenevolentAI lists on Euronext Amsterdam BenevolentAI provides an update on its business priorities Benevolent Platform | AI-enabled Drug Discovery | BenevolentAI About us | BenevolentAI | AI Drug Discovery
- End-to-End Drug Discovery
  
  Benevolent Platform
  
  A versatile, scalable and robust AI-enabled drug discovery platform built with expert scientists, leveraging multi-modal data foundations.
  
  Benevolent Platform
Benevolent Platform

Benevolent Platform

A versatile, scalable and robust AI-enabled drug discovery platform built with expert scientists, leveraging multi-modal data foundations.

Benevolent Platform
- BEN-8744 | Ulcerative colitis
  
  Pipeline
  
  BenevolentAI has a rich drug pipeline that mixes both potentially best-in-class and first-in-class drug candidates, all entirely generated using the Benevolent Platform™.
  
  Pipeline
- BEN-28010 | Glioblastoma multiforme
- BEN-34712 | ALS
- Parkinson's disease
- Fibrosis
Pipeline

Pipeline

BenevolentAI has a rich drug pipeline that mixes both potentially best-in-class and first-in-class drug candidates, all entirely generated using the Benevolent Platform™.

Pipeline
Partnering

Partnering

We partner with leading pharmaceutical and biotech companies to tackle therapeutic challenges from new angles and develop novel drugs for complex multifactorial diseases.

Partnering
- - Announcement alerts
    
    Investors
    
    Our investor relations page contains information about BenevolentAI's business for potential investors and analysts: investor presentations, annual reports, governance and events.
    
    Investors
  Announcements
  
  Investors
  
  Our investor relations page contains information about BenevolentAI's business for potential investors and analysts: investor presentations, annual reports, governance and events.
  
  Investors
- Reports and presentations
  
  Investors
  
  Our investor relations page contains information about BenevolentAI's business for potential investors and analysts: investor presentations, annual reports, governance and events.
  
  Investors
- General meetings
  
  Investors
  
  Our investor relations page contains information about BenevolentAI's business for potential investors and analysts: investor presentations, annual reports, governance and events.
  
  Investors
- Governance
  
  Investors
  
  Our investor relations page contains information about BenevolentAI's business for potential investors and analysts: investor presentations, annual reports, governance and events.
  
  Investors
- Share Capital
  
  Investors
  
  Our investor relations page contains information about BenevolentAI's business for potential investors and analysts: investor presentations, annual reports, governance and events.
  
  Investors
- Business combination
  
  Investors
  
  Our investor relations page contains information about BenevolentAI's business for potential investors and analysts: investor presentations, annual reports, governance and events.
  
  Investors
- Financial calendar
  
  Investors
  
  Our investor relations page contains information about BenevolentAI's business for potential investors and analysts: investor presentations, annual reports, governance and events.
  
  Investors
- Investor resources
  
  Investors
  
  Our investor relations page contains information about BenevolentAI's business for potential investors and analysts: investor presentations, annual reports, governance and events.
  See Also
  BENEVOLENTAI S.A. » Koers Aandeel | IEX.nl
  
  Investors
- Analyst coverage
  
  Investors
  
  Our investor relations page contains information about BenevolentAI's business for potential investors and analysts: investor presentations, annual reports, governance and events.
  
  Investors
Investors

Investors

Our investor relations page contains information about BenevolentAI's business for potential investors and analysts: investor presentations, annual reports, governance and events.

Investors
- Press releases and in the media
  
  News and media
  
  Get the latest news and updates from BenevolentAI on our AI-driven drug and research programmes, collaborations, investments and events.
  
  News and media
- Blog and videos
  
  News and media
  
  Get the latest news and updates from BenevolentAI on our AI-driven drug and research programmes, collaborations, investments and events.
  
  News and media
- Events
  
  News and media
  
  Get the latest news and updates from BenevolentAI on our AI-driven drug and research programmes, collaborations, investments and events.
  
  News and media
- Newsletter
  
  News and media
  
  Get the latest news and updates from BenevolentAI on our AI-driven drug and research programmes, collaborations, investments and events.
  
  News and media
- Press kit
  
  News and media
  
  Get the latest news and updates from BenevolentAI on our AI-driven drug and research programmes, collaborations, investments and events.
  
  News and media
News and media

News and media

Get the latest news and updates from BenevolentAI on our AI-driven drug and research programmes, collaborations, investments and events.

News and media
- Culture blog
  
  Careers
  
  Join us to work on a mission that matters: uniting AI and cutting-edge science to discover and develop new medicines for complex diseases.
  
  Careers
- Join our team
  
  Careers
  
  Join us to work on a mission that matters: uniting AI and cutting-edge science to discover and develop new medicines for complex diseases.
  
  Careers
Careers

Careers

Join us to work on a mission that matters: uniting AI and cutting-edge science to discover and develop new medicines for complex diseases.

Careers

Home
Investors

BUSINESS OVERVIEW

BenevolentAI (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery.

BenevolentAI is a leading developer of advanced artificial intelligence technologies that unlock the value of multimodal data, surface novel insights, and accelerate biomedical discovery

Through the combined capabilities of its AI platform, its scientific expertise, and wet-lab facilities, the Company is developing an inhouse drug pipeline of high-value assets. The Company is headquartered in London, with a research facility in Cambridge (UK) and a further office in New York.

Our pipeline